Prathyusha Durabaibu
Vermögen: 614 639 $ am 31.05.2026
Vermögen: 614 639 $ am 31.05.2026
Prathyusha Durabaibu is currently an Independent Director at Organogenesis Holdings, Inc. since 2021.
Formerly, Ms. Durabaibu was Controller at Pacific Biosciences of California, Inc. from 2010 to 2019 and Principal Financial Officer at Sangamo Therapeutics, Inc. from 2025 to 2026.
Education includes an undergraduate degree from Oxford Brookes University and an MBA from San Jose State University.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.04.2026 | 198’219 ( 0.15% ) | 509 423 $ | 31.05.2026 | |
| 22.01.2026 | 482’645 ( 0.12% ) | 105 217 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| ORGANOGENESIS HOLDINGS INC. | Direktor/Vorstandsmitglied | 19.11.2021 |
| Unternehmen | Position | Ende |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Finanzdirektor/CFO | 03.02.2026 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. | Comptroller/Controller/Auditor | 01.03.2019 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. BiotechnologyHealth Technology Operates as a genomic medicine company | Health Technology |
Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. Medical SpecialtiesHealth Technology Designs, develops and manufactures sequencing system products to help scientists to resolve genetically complex problems | Health Technology |
Oxford Brookes University
Oxford Brookes University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
San Jose State University
San Jose State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Organogenesis Holdings, Inc.
Organogenesis Holdings, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and commercializes regenerative medicines products for the advanced wound care and surgical and sports medicine markets | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen